News and Comments

CHEMOCENTRIX (CCXI): A LEADER OF A NEW LINE OF INVESTIGATIONAL TREATMENTS

  Monday, October 08, 2012

In an effort to find additional small biotech firms with solid scientific fundamentals and products that promise reaching beyond the limiting horizon, we pinpointed ten to date. We picked them from among one hundred biotech firms that have little, or none of the properties that make out   super achievers. We decided to go on and start with a company called ChemoCentryx (CCXI). Our selection was not based on priority, preference, or any other reason that might insinuate advantages over the other nine firms we picked for comprehensive reviewing. It was rather based on curiosity triggered by a recent announcement by the firm of preclinical results of a small molecule oral drug CCX872 aimed at blocking the chemokine receptor CCR2 for the treatment of diabetes nephropathy.  More...


Recent News_and_Comments


Archive


Tags